Nasdaq warns DocGo (NASDAQ: DCGO) over minimum $1 bid deficiency

Rhea-AI Filing Summary

DocGo Inc. has been notified by Nasdaq that its stock no longer meets the exchange’s $1.00 minimum bid price requirement. Nasdaq reviewed closing bid prices between December 9, 2025 and January 23, 2026 and found the shares below the threshold, triggering a compliance notice.

The company keeps its current Nasdaq Capital Market listing for now and has until July 27, 2026 to lift its closing bid to at least $1.00 for ten consecutive business days. If it still falls short, DocGo may seek a second 180-day grace period, potentially including a reverse stock split to restore compliance.

Positive

• None.

Negative

• Nasdaq minimum bid-price deficiency places DocGo’s Nasdaq Capital Market listing at risk, with potential delisting if the share price does not reach at least $1.00 for ten consecutive business days by July 27, 2026 or within any subsequent compliance period.

Insights

Equity analyst

Nasdaq bid-price deficiency raises listing risk and potential reverse split.

DocGo received a Nasdaq notice that its common stock’s closing bid stayed below $1.00 from December 9, 2025 to January 23, 2026, violating the minimum bid requirement for continued listing on the Nasdaq Capital Market.

The company has until July 27, 2026 to regain compliance by having a closing bid at or above $1.00 for ten consecutive business days. A second 180-day period is possible if it meets other initial listing standards and formally outlines a cure plan.

The filing notes DocGo may consider a reverse stock split as one option to restore the share price. If Nasdaq ultimately concludes the deficiency cannot be cured or eligibility criteria are not met, the stock could face delisting, though DocGo would have the right to appeal to a Nasdaq hearings panel.

0001822359FALSE00018223592026-01-262026-01-26

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________

FORM 8-K

___________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): January 26, 2026

___________________________________

DOCGO INC.

(Exact name of registrant as specified in its charter)

___________________________________

Delaware

001-39618

85-2515483

(State or other jurisdiction of incorporation or organization)

(Commission File Number)

(I.R.S. Employer Identification No.)

685 Third Avenue, 9th Floor, New York, New York

10017

(Address of principal executive offices)

(Zip Code)

(844) 443-6246

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

___________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common stock, par value $0.0001 per share

DCGO

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 12b-2 of the Exchange Act.

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On January 26, 2026, DocGo Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upon the closing bid price of the Company’s common stock, par value $0.0001 per share (“Common Stock”), from December 9, 2025 to January 23, 2026, the Company is not currently in compliance with Nasdaq Listing Rule 5550(a)(2), which requires the Company to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market (the “Minimum Bid Requirement”).

The Notice has no immediate effect on the continued listing status of the Common Stock on The Nasdaq Capital Market, and therefore, the Company’s listing remains fully effective.

In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days from the date of the Notice—or until July 27, 2026—to regain compliance with the Minimum Bid Requirement. To regain compliance, the closing bid of the Common Stock must meet or exceed $1.00 per share for a minimum of ten consecutive business days prior to July 27, 2026.

If the Company is not in compliance with the Minimum Bid Requirement by July 27, 2026, the Company may be eligible for a second 180 calendar day compliance period. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Requirement, and the Company would be required to notify Nasdaq of its intent to cure the deficiency during the second compliance period, which may include effecting a reverse stock split, if necessary. If the Company meets these requirements, Nasdaq will inform the Company that it has been granted an additional 180 calendar days. However, if it appears to the Staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice that the Company’s securities are subject to delisting. The Company would then be entitled to appeal that determination to a Nasdaq hearings panel.

While there can be no assurance that the Company will regain compliance with the Minimum Bid Requirement during the 180 day compliance period, secure a second period of 180 days to regain compliance, or maintain compliance with the other Nasdaq listing requirements, the Company intends to actively monitor the closing bid price of the Common Stock and will evaluate available options to regain compliance with the Minimum Bid Requirement, including initiating a reverse stock split.

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DOCGO INC.
By:			/s/ Norman Rosenberg
Name:			Norman Rosenberg
Title:			Chief Financial Officer and Treasurer

Date: January 30, 2026

2

FAQ

What Nasdaq issue did DocGo (DCGO) disclose in this 8-K?

DocGo disclosed that Nasdaq notified the company its common stock failed to meet the $1.00 minimum bid price requirement. The closing bid stayed below $1.00 between December 9, 2025 and January 23, 2026, triggering a formal deficiency notice.

Does the Nasdaq notice immediately delist DocGo stock?

The notice does not immediately delist DocGo’s stock. The company’s Nasdaq Capital Market listing remains fully effective while it has an initial 180-day grace period to regain compliance with the $1.00 minimum bid price requirement.

How long does DocGo have to fix its Nasdaq bid-price deficiency?

DocGo has until July 27, 2026 to regain compliance. The stock’s closing bid must be at or above $1.00 for at least ten consecutive business days within this 180-day period to satisfy Nasdaq’s minimum bid requirement.

Can DocGo get more time beyond July 27, 2026 to regain compliance?

DocGo may qualify for a second 180-day compliance period if it meets Nasdaq’s initial listing standards other than the bid-price rule and informs Nasdaq of its plan to cure the deficiency during that additional period.

What steps might DocGo take to regain Nasdaq compliance?

DocGo plans to monitor its closing bid price and evaluate options to restore compliance with the $1.00 minimum bid requirement, which the company states may include initiating a reverse stock split if necessary during the allowed compliance periods.

What happens if DocGo ultimately fails to meet Nasdaq’s bid rule?

If DocGo cannot regain compliance or qualify for another grace period, Nasdaq may move to delist its securities. DocGo would then be entitled to appeal the determination to a Nasdaq hearings panel, as described in the disclosure.